CINECA IRIS Institutional Research Information System

SINICCO, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.061
EU - Europa 858
AS - Asia 427
AF - Africa 4
SA - Sud America 1
Totale 2.351
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.038
CN - Cina 298
UA - Ucraina 122
IE - Irlanda 120
DE - Germania 96
FR - Francia 94
SE - Svezia 92
IT - Italia 91
FI - Finlandia 78
KR - Corea 73
DK - Danimarca 51
GB - Regno Unito 48
SG - Singapore 39
AT - Austria 36
CA - Canada 23
PL - Polonia 16
VN - Vietnam 11
BE - Belgio 10
IN - India 6
NL - Olanda 3
MU - Mauritius 2
SN - Senegal 2
PE - Perù 1
RU - Federazione Russa 1
Totale 2.351
Salva come PNG Salva come JPEG
Città #
Beijing 264
Ann Arbor 164
Chandler 154
Dublin 120
Jacksonville 70
Villeurbanne 68
Houston 45
Princeton 44
Medford 43
Dearborn 41
Ashburn 37
Vienna 36
Singapore 29
Milan 24
Boston 19
Toronto 17
Nyköping 16
Warsaw 16
Wilmington 15
Boardman 13
Brussels 10
Verona 9
Woodbridge 9
Falls Church 7
Kunming 7
Lachine 6
New York 6
Norwalk 6
Torino 6
Bisignano 4
Dong Ket 4
Jinan 4
Mountain View 4
Nanjing 4
Fremont 3
Kharkiv 3
Munich 3
Portici 3
Pune 3
Redmond 3
Redwood City 3
Battipaglia 2
Hebei 2
Hefei 2
Napoli 2
Palermo 2
Rome 2
Sant'angelo Romano 2
Santa Clara 2
Trieste 2
Anzio 1
Auburn Hills 1
Avigliano 1
Berlin 1
Caserta 1
Crotone 1
Easton 1
Fairfield 1
Fuzhou 1
Guangzhou 1
Gurgaon 1
Huzhou 1
Lima 1
Los Angeles 1
Nanchang 1
Nantong 1
Saint Petersburg 1
San Mateo 1
Shanghai 1
Trento 1
Wuhan 1
Xian 1
Zhengzhou 1
Zhongxin 1
Totale 1.384
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients 148
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 136
Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis. 107
Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus 102
Cytokine network and acute primary HIV-1 infection. 94
Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient 91
FARMACOCINETICA DEI FARMACI ANTIRETROVIRALI NELLA PRATICA CLINICA 87
Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens. 83
The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters 80
Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20) 70
Polyamines in lymphocytes from patients infected by human immunodeficiency virus. 69
Longitudinal analysis of the 90K glycoprotein in the Italian HIV-seroconversion study: temporal trend and predictability of the maturity of HIV infection. 66
Oral lesions in children born to HIV-1 positive women. 64
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon 63
Cut-off values of ribavirin trough concentration for sustained virological response and for hematological toxicity in HCV/HIV-co-infected patients treated with RBV and Pegylated Interferon 63
Clinical pharmacology of antiretroviral therapy 60
Immunoglobulin and Myc gene structure in lymphnode biopsies from HIV-positive patients with LAS and lymphoma. 59
Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. 59
An outbreak of HIV-1 subtype G among Italian injecting drug users. 57
EFFETTO DI LOPINAVIR/RITONAVIR SULLE CONCENTRAZIONI PLASMATICHE DI TRIGLICERIDI E COLESTEROLO: VALUTAZIONE FARMACOCINETICA 57
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide 57
Asymptomatic women at high risk of vertical HIV-1 transmission to their fetuses. 56
Clearance of 14-3-3 protein from cerebrospinal fluid heralds the resolution of bacterial meningitis. 56
Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting. 53
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting 53
Lopinavir protein binding in vivo through the 12-hour dosing interval 49
Penetration of didanosine in semen of HIV-1-infected men 49
Impact of nevirapine (NVP) trough concentrations (Ctrough) on time to achieve and time maintenance of viral suppression (VS) in HIV+ patients taking NVP-based regimens 45
Successful simplification of HAART in patients with acute primary HIV infection. 44
UTILITA' DEL THERAPEUTIC DRUG MONITORING DI NEVIRAPINA 44
Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine 41
Treating advanced HIV infection. 41
Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting. 39
Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. 37
The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy 36
Pharmacokinetics of saquinavir co-administered with cimetidine. 35
Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. 35
The relationship between nevirapine plasma concentrations and abnormal liver function tests 35
The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. 29
Totale 2.449
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.786
article - articoli 0
book - libri 0
conference - conferenze 1.645
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.431
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020348 0 15 30 30 36 60 55 9 37 26 33 17
2020/2021267 42 1 40 12 16 11 23 2 48 33 10 29
2021/2022329 13 16 18 19 15 10 29 21 12 10 75 91
2022/2023462 53 10 7 42 54 132 39 28 65 4 16 12
2023/2024171 40 36 6 6 8 27 0 11 0 0 11 26
2024/202510 0 10 0 0 0 0 0 0 0 0 0 0
Totale 2.449